Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Recent Articles
Small Retrospective Study Suggests Thrombopoietin Receptor Agonists Are Safe, Likely Effective for ITP During...
Preliminary findings from an observational multicenter study suggest that temporary off-label use of thrombopoietin receptor agonists (TPO-RAs) for the treatment of severe and/or refractory...
How I Teach: Navigating the COVID Classroom
As the COVID-19 pandemic increased rapidly in the U.S. in March and April 2020, the Association of American Medical Colleges (AAMC) released guidance strongly...
Inhaled Vaporized Cannabis Yields No Analgesic Benefit in Patients With SCD
Inhalation of vaporized cannabis did not significantly reduce self-reported pain levels or disease-related symptoms in adults with sickle cell disease (SCD) compared with placebo,...
NIH Trials Test Anticoagulants for Treating COVID-19
The NIH has launched two of three phase III clinical trials to test the safety and efficacy of different anticoagulants, including heparin and apixaban,...
New York Genome Center Awards Grants to Close Racial Gaps in Cancer Research
As part of its Polyethnic-1000 initiative to increase understanding of racial disparities in the prevalence of certain cancers, The New York Genome Center has...
Current Issue
September 2020 Volume 6, Issue 11
This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.